Table 2.
Baseline CV Measurements, Risk Factors and Inflammatory Markers
| Completers (n=108), Mean (SD) | All Subjects (n=143), Mean (SD) | |
|---|---|---|
| Brachial SBP, mm Hg | 131.5 (17.6) | 131.9 (17.7) |
| Brachial DBP, mm Hg | 78.7 (10.7) | 78.6 (11.0) |
| Aortic PP, mm Hg | 46.0 (14.9) | 45.1 (14.3) |
| Aortic DP, mm Hg | 124.4 (18.4) | 123.5 (18.4) |
| Augmentation index | 28.6 (12.0) | 28.3 (11.5) |
| BMI | 29.5 (6.7) | 29.8 (6.8) |
| hsCRP, mg/dL | 4.2 (6.2) | 5.3 (10.5) |
| Framingham composite score, % | 3.9 (5.3) | 3.7 (4.9) |
| MCP‐1*, pg/mL | 473.2 (250.77) | 471.9 (294.96) |
| IL‐17*, pg/mL | 60.5 (642.6) | 17.1 (642.3) |
| IL‐6*, pg/mL | 1.0 (6.4) | 1.4 (6.2) |
| Total cholesterol, mg/dL | 186.8 (41.7) | 186.0 (41.7) |
| Triglycerides, mg/dL | 110.4 (59.8) | 109.6 (59.5) |
| HDL, mg/dL | 65.3 (18.0) | 65.2 (17.7) |
| LDL, mg/dL | 111.3 (35.5) | 111.1 (35.2) |
| Fasting serum insulin, μU/mL | 20.3 (10.9) | 21.2 (12.3) |
| Fasting glucose, mg/dL | 95.6 (11.6) | 95.0 (11.0) |
| HOMA‐IR, mg/dL×μU/mL | 5.0 (3.4) | 5.1 (3.4) |
| FMD, % | 8.8 (4.2, 48%*) | 8.3 (4.0, 48%*) |
| NMD, % | 1.9 (1.6, 84%*) | 2.0 (1.6, 80%*) |
| PWV, m/s | 9.0 (2.6, 29%*) | 9.2 (2.8, 30%*) |
| RHI, % | 2.1 (0.7, 33%*) | 2.1 (0.7, 33%*) |
BMI indicates body mass index; CV, cardiovascular; DBP, diastolic blood pressure; FMD, flow‐mediated dilatation; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment‐insulin resistance; hsCRP, high‐sensitivity C‐reactive protein; DP, delta pressure; IL, interleukin; LDL, low‐density lipoprotein; MCP‐1, monocyte chemotactic protein‐1; NMD, nitroglycerin‐mediated dilatation; PP, pulse pressure; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure.
*
Median(IQ).
*
Coefficient of variation.